[Intraperitoneal lymphatic chemotherapy for colonic cancer].
OBJECTIVE
To evaluate the effect of intraperitoneal lymphatic chemotherapy with carboplatin and sandostatin on colonic carcinoma and abdominal lymphatic metastasis in patients after radical resection.


METHODS
Patients with colonic cancer were divided into two group: abdominal lymphatic chemotherapy group and control group. The lymphatic chemotherapy group was treated at the introduction stage of anesthesia with carboplatin (200 mg) injected intraperitoneally and sandostatin (0.1 mg x 2) injected subcutaneously, whereas the control group was just treated with carboplatin (200 mg) injected intraperitoneally. The platinum levels in abdominal lymphatic nodes were monitored during operation. The two groups were uninterruptedly given intraperitoneal lymphatic chemotherapy or intraperitoneal chemotherapy. Retroperitoneal lymphatic metastasis was evaluated in each patient by abdominal CT scan after operation.


RESULTS
The platinum levels in abdominal lymphatic nodes increased more significantly at 2, 3 hours in the lymphatic chemotherapy group than in the control group (P < 0.01). There was no difference in the platinum levels of the portal vein between the two groups, and also no difference in the platinum levels between the lymphatic nodes with or without metastasis. The rates of retroperitoneal lymphatic metastasis after resection were significantly lower in the lymphatic chemotherapy group control group (P < 0.01).


CONCLUSIONS
Intraperitoneal administration of carboplatin combined with sandostatin may elevate the platinum levels in the abdominal lymphatic nodes and reduce the abdominal lymphatic metastasis after radical resection of colonic cancer. It is an effective method for intraperitoneal lymphatic chemotherapy.
Wang
Q
Q
Department of General Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Wang
S
S
Sun
Y
Y
Ruan
C
C
Liu
X
X
Liu
Y
Y
Wang
Y
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage; D016896:Treatment Outcome
D016190:Carboplatin; D015282:Octreotide